verified SJR 0,966 · Q1 • database Scopus / SJR & Web of Science & DOAJ indexed

United Kingdom · SAGE Publications Inc.

workspace_premium Q1 — Medicine (miscellaneous) visibility_off Single blind Peer Review lock_open Open Access · DOAJ

Therapeutic Advances in Chronic Disease

Therapeutic Advances in Chronic Disease is a journal indexed in SJR in Medicine (miscellaneous) with an H index of 54. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1800 €. The scope of the journal is focused on pharmacology, chronic conditions, chronic diseases. It has an SJR impact factor of 0,966 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 0,966.

ISSN: 2040-6223

Publisher: SAGE Publications Inc.

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science verifiedDOAJ

open_in_new Portal NPD menu_book Author guidelines

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,966 Q1

H-index 54

Acceptance rate pie_chart

33%

Source Acceptance_Rate

Time to publication hourglass_top

12 weeks

Field Average_time_publication_weeks

Publication cost (APC) payments

1.800 € Open Access

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science DOAJ

SJR Impact

0,966

H-index

Docs (year)

Docs 3y

317

Total refs

1735

Cites 3y

998

Citable 3y

307

Cites/Doc 2y

2.96

Ref/Doc

45.66

Immediate OA

1800 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Carotid stenting with proximal cerebral protection in symptomatic low-grade vulnerable recurrent carotid stenosis

Vedolizumab: an a4beta7 integrin antagonist for ulcerative colitis and Crohn's disease

Dietary factors and the risk of glaucoma: a review

Developments in rare bone diseases and mineral disorders

Dealing with uncertainty in the treatment of Helicobacter pylori

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications

Current and emerging therapies for the management of functional gastrointestinal disorders

Contributors, risk associates, and complications of frailty in patients with chronic kidney disease: a scoping review

Comparing iStent versus CyPass with or without phacoemulsification in patients with glaucoma: a meta-analysis

Cognitive dysfunction with aging and the role of inflammation

Clinical applications for out-of-office blood pressure monitoring

Characterization of diabetes risk factors in patients prescribed chronic statin therapy

SHOW MORE ARTICLES

CD4+/CD8+ ratio positively correlates with coronary plaque instability in unstable angina pectoris patients but fails to predict major adverse cardiovascular events

A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy

Assessing the incidence of acidosis in patients receiving metformin with and without risk factors for lactic acidosis

Asenapine in bipolar I disorder: evidence and place in patient management

Argatroban in heparin-induced thrombocytopenia: rationale for use and place in therapy

Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis

Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects

Age-related macular degeneration: current treatment and future options

Advanced virtual reality-based rehabilitation of balance and gait in clinical practice

Acute severe ulcerative colitis: latest evidence and therapeutic implications

Achieving appropriate regulations for electronic cigarettes

A review of ultrabrief pulse width electroconvulsive therapy

FAQs

Therapeutic Advances in Chronic Disease has an SJR of 0,966 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 1800 EUR.

The acceptance rate recorded for Therapeutic Advances in Chronic Disease is 33%.

Therapeutic Advances in Chronic Disease

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Therapeutic Advances in Chronic Disease?

What is the APC / publication cost?

What is the acceptance rate?